127 related articles for article (PubMed ID: 35533722)
1. Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.
Picozza M; Cristofoletti C; Bresin A; Fioretti M; Sambucci M; Scala E; Monopoli A; Cantonetti M; Pilla MA; Accetturi MP; Borsellino G; D'Atri S; Caprini E; Russo G; Narducci MG
J Invest Dermatol; 2022 Nov; 142(11):3009-3019.e9. PubMed ID: 35533722
[TBL] [Abstract][Full Text] [Related]
2. The abnormal function of CD39
Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
[TBL] [Abstract][Full Text] [Related]
3. CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome.
Yakymiv Y; Marchisio S; Ortolan E; Bracci C; Senetta R; Rumore MR; Tampieri C; Fia M; Ribero S; Funaro A; Quaglino P
Blood; 2023 Jan; 141(1):111-116. PubMed ID: 36040496
[No Abstract] [Full Text] [Related]
4. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
5. A single-nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Turner RJ; Sluyter R; Watson D
Immunol Cell Biol; 2020 May; 98(5):397-410. PubMed ID: 32181525
[TBL] [Abstract][Full Text] [Related]
6. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
[TBL] [Abstract][Full Text] [Related]
7. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice.
Gao J; Ren S; Choonoo G; Chen G; Frleta D; Zhong J; Gupta N; Sharma P; Oyejide A; Atwal GS; Macdonald L; Murphy A; Kuhnert F
Dis Model Mech; 2023 Oct; 16(10):. PubMed ID: 37718909
[TBL] [Abstract][Full Text] [Related]
9. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
10. The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation.
Rissiek A; Baumann I; Cuapio A; Mautner A; Kolster M; Arck PC; Dodge-Khatami A; Mittrücker HW; Koch-Nolte F; Haag F; Tolosa E
J Autoimmun; 2015 Apr; 58():12-20. PubMed ID: 25640206
[TBL] [Abstract][Full Text] [Related]
11. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.
Narducci MG; Arcelli D; Picchio MC; Lazzeri C; Pagani E; Sampogna F; Scala E; Fadda P; Cristofoletti C; Facchiano A; Frontani M; Monopoli A; Ferracin M; Negrini M; Lombardo GA; Caprini E; Russo G
Cell Death Dis; 2011 Apr; 2(4):e151. PubMed ID: 21525938
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection.
Jenabian MA; Seddiki N; Yatim A; Carriere M; Hulin A; Younas M; Ghadimi E; Kök A; Routy JP; Tremblay A; Sévigny J; Lelievre JD; Levy Y
PLoS Pathog; 2013; 9(4):e1003319. PubMed ID: 23658513
[TBL] [Abstract][Full Text] [Related]
15. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Cristofoletti C; Bresin A; Picozza M; Picchio MC; Monzo F; Helmer Citterich M; Passarelli F; Frezzolini A; Scala E; Monopoli A; Cantonetti M; Benucci R; D'Atri S; Caprini E; Russo G; Narducci MG
Leukemia; 2019 May; 33(5):1231-1242. PubMed ID: 30518812
[TBL] [Abstract][Full Text] [Related]
16. Imbalanced IL-1B and IL-18 Expression in Sézary Syndrome.
Manfrere KCG; Torrealba MP; Ferreira FM; de Sousa ESA; Miyashiro D; Teixeira FME; Custódio RWA; Nakaya HI; Ramos YAL; Sotto MN; Woetmann A; Ødum N; Duarte AJDS; Sanches JA; Sato MN
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902104
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
18. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
20. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
